Alessandro De Falco

Dr. Alessandro De Falco

DMMBM, University Federico II, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
ABAlessandro Bruselles
Alessandro Bruselles
CMCecilia Mancini
Cecilia Mancini
LCLuigi Chiriatti
Luigi Chiriatti
MCMattia Carvetta
Mattia Carvetta
MBMaria Chiara Baroni
Maria Chiara Baroni
MTMarco Tartaglia
Marco Tartaglia

31 October 2024 in Children
Verified
Journal Article
Open access
PDF file
APANTONIA PASCARELLA
ANTONIA PASCARELLA
Giuseppe LimongelliGiuseppe Limongelli
Giuseppe Limongelli
AFAlessandro De Falco
Alessandro De Falco
EMElia Marco Paolo Minale
Elia Marco Paolo Minale
GNGiangiacomo Di Nardo
Giangiacomo Di Nardo
DBDaniele De Brasi
Daniele De Brasi
RASopathies are a group of genetic syndromes caused by germline mutations in genes involved in the RAS/Mitogen-Activated Protein Kinase signaling pathway, which regulates cellular proliferation, differentiation, and angiogenesis. Despite their involvement at different levels of this pathway, RASopathies share overlapping clinical phenotypes. Noonan syndrome is the most prevalent RASopathy, with an estimated incidence of 1 in 2500 live births, and it is typically inherited in an autosomal dominant manner, with 50% of cases involving gain-of-function mutations in the PTPN11 gene. De novo mutations are common, accounting for 60% of cases. The phenotype of Noonan syndrome includes characteristic facial and physical features, congenital cardiac defects, lymphatic and cerebrovascular anomalies, renal malformations, hematological abnormalities, developmental issues, and an increased risk of cancer. Severe congenital cardiac defects and lymphatic abnormalities significantly impact prognosis, contributing to increased morbidity and mortality. Recent therapeutic advancements have introduced trametinib, an MEK1/2 inhibitor, for treating Noonan syndrome patients with severe cardiac and lymphatic complications. To assess its efficacy, here, we present a case of a newborn with Noonan syndrome who exhibited refractory chylothorax, ventricular hypertrophy, and pulmonary stenosis who was treated with trametinib. The patient demonstrated significant improvement in chylothorax and left ventricular hypertrophy, though pulmonary stenosis persisted. This case further confirms trametinib’s potential as a therapeutic option for severe Noonan syndrome complications, emphasizing the need for further clinical trials to optimize treatment protocols and evaluate long-term outcomes.

1 December 2025 in Neurology Genetics
Verified
Journal Article
Open access
PLPasquale Di Letto
Pasquale Di Letto
CLChiara De Leonibus
Chiara De Leonibus
FPFrancesca Pia Palmieri
Francesca Pia Palmieri
MZMariateresa Zanobio
Mariateresa Zanobio
MSMargherita Scarpato
Margherita Scarpato
APAngela Peron
Angela Peron
Neurodevelopmental disorders (NDDs) are often the results of genetic factors, whose identification and key role in their etiology may be elusive. Despite advancements in genetic testing, many cases remain unsolved. Single-nucleotide variants in a critical 18-bp region of the noncoding gene RNU4-2, a crucial component of the spliceosome complex, have been recently recognized as being responsible for ReNU syndrome, also known as NDD with hypotonia, brain anomalies, distinctive facies, and absent language (NEDHAFA). The aim of this study was to investigate the prevalence of RNU4-2 variants within a cohort of unsolved patients exhibiting NDDs from the Telethon Undiagnosed Disease Program (TUDP). We conducted a reanalysis of genomic data using bioinformatic tools, followed by direct sequencing to identify variants in the RNU4-2 critical region. Causative variants were detected in 11 of 375 tested individuals, allowing us to diagnose 2.93% of our unsolved cohort. All heterozygous variants in RNU4-2 occurred de novo, including 10 with the recurrent n.64_65insT insertion and 1 with n.77_78insT. Structural modeling suggested that these variants disrupt the U4/U6 snRNA interaction, potentially impairing spliceosome function. Our findings reinforce the critical role of RNU4-2 variants in syndromic NDDs and underscore the importance of noncoding regions in genetic diagnoses. These findings show that RNU4-2 variants account for approximately 2.9% of the patients with TUDP in this study and highlight the need for integrating advanced molecular techniques and data sharing to refine diagnoses and enhance our understanding of rare genetic disorders.

4 December 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
AFAlessandro De Falco
Alessandro De Falco
EMElia Marco Paolo Minale
Elia Marco Paolo Minale
CMCamilla Meossi
Camilla Meossi
SPStefano Pagano
Stefano Pagano
RTRosanna Trovato
Rosanna Trovato
CPCarmelo Piscopo
Carmelo Piscopo

16 February 2025 in Genes
Verified
Journal Article
Open access
PDF file
SPStefano Pagano
Stefano Pagano
DLDiego Lopergolo
Diego Lopergolo
AFAlessandro De Falco
Alessandro De Falco
CMCamilla Meossi
Camilla Meossi
SSSara Satolli
Sara Satolli
FSFilippo M. Santorelli
Filippo M. Santorelli
Background/Objectives: Schuurs–Hoeijmakers syndrome (SHMS), also known as PACS1 neurodevelopmental disorder, is a rare condition characterized by intellectual disability, distinctive craniofacial abnormalities, and congenital malformations. SHMS has already been associated with variants in the PACS1 gene in 63 patients. In this study, we describe 10 new Italian SHMS patients all harboring the common de novo p.(Arg203Trp) variant. Methods: The 10 patients we studied were evaluated by clinical geneticists and child neurologists and a detailed description of clinical features was recorded. Data were then coded using the Human Phenotype Ontology (HPO) terms. The recurrent p.(Arg203Trp) variant in PACS1 was identified by clinical exome sequencing or whole exome sequencing in trio using standard methodologies. To facilitate mutation identification, we designed a new PCR-RFLP strategy adopting the endonuclease DpnII. Results: We define a detailed clinical phenotyping in patients with intellectual disability and facial characteristics (thick eyebrows, down-slanting palpebral fissures, ocular hypertelorism, low-set ears, a thin upper lip, and a wide mouth) that can help clinicians form a more efficient diagnosis of SHMS even through neuroimaging and neuropsychological evaluation. Conclusions: Our series of 10 newly affected Italian children highlights specific clinical features that may help clinicians recognize and better manage this syndrome, contributing to precision medicine approaches in medical genetics.

27 December 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
AFAlessandro De Falco
Alessandro De Falco
MKMarianthi Karali
Marianthi Karali
CCChiara Criscuolo
Chiara Criscuolo
FTFracesco Testa
Fracesco Testa
MBMaria Rosaria Barillari
Maria Rosaria Barillari
Nicola Brunetti-PierriNicola Brunetti-Pierri
Nicola Brunetti-Pierri
Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome type A) is an autosomal recessive lysosomal storage disorder caused by pathogenic variants in the SGSH gene encoding N‐sulfoglucosamine sulfohydrolase, an enzyme involved in the degradation of heparan sulfate. MPS IIIA is typically characterized by neurocognitive decline and hepatosplenomegaly with childhood onset. Here, we report on a 53‐year‐old male subject initially diagnosed with Usher syndrome for the concurrence of retinitis pigmentosa and sensorineural hearing loss. Clinical exome sequencing identified biallelic missense variants in SGSH, and biochemical assays showed complete deficiency of sulfamidase activity and increased urinary glycosaminoglycan excretion. Reverse phenotyping revealed left ventricle pseudo‐hypertrophy, hepatosplenomegaly, bilateral deep white matter hyperintensities upon brain MRI, and decreased cortical metabolic activity by PET‐CT. On neuropsychological testing, the proband presented only partial and isolated verbal memory deficits. This case illustrates the power of unbiased, comprehensive genetic testing for the diagnosis of challenging mild or atypical forms of MPS IIIA.